checkpoint.jpg
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
July 15, 2024 08:00 ET | Checkpoint Therapeutics, Inc
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM,...
checkpoint.jpg
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
July 02, 2024 07:00 ET | Checkpoint Therapeutics, Inc
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has...
checkpoint.jpg
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
June 24, 2024 07:30 ET | Checkpoint Therapeutics, Inc
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has...
July 30, 2021 - ROSEN LOGO.jpg
CKPT SHAREHOLDER ALERT: TOP RANKED ROSEN LAW FIRM Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action – CKPT
May 23, 2024 12:38 ET | The Rosen Law Firm PA
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March...
checkpoint.jpg
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024 08:30 ET | Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James...
checkpoint.jpg
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
May 10, 2024 08:30 ET | Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
checkpoint.jpg
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
March 22, 2024 08:30 ET | Checkpoint Therapeutics, Inc
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced...
checkpoint.jpg
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
December 05, 2023 08:30 ET | Checkpoint Therapeutics, Inc
Upcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc....
checkpoint.jpg
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
November 13, 2023 17:00 ET | Checkpoint Therapeutics, Inc
Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 Recent publication of cosibelimab pivotal trial results in the Journal for ImmunoTherapy...
checkpoint.jpg
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer
October 18, 2023 08:30 ET | Checkpoint Therapeutics, Inc
Cosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous...